{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:26:41Z","timestamp":1740130001288,"version":"3.37.3"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"W1","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31771462","81772614","U1611261","31801105","81802438"],"award-info":[{"award-number":["31771462","81772614","U1611261","31801105","81802438"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2017YFA0106700"],"award-info":[{"award-number":["2017YFA0106700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Program for Guangdong Introducing Innovative and Entrepreneurial Teams","award":["2017ZT07S096"],"award-info":[{"award-number":["2017ZT07S096"]}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"publisher","award":["2020A1515010220"],"award-info":[{"award-number":["2020A1515010220"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immune checkpoint blockade (ICB) therapy has been successfully applied to clinically therapeutics in multiple cancers, but its efficacy varies greatly among different patients and cancer types. Therefore, the construction of gene signatures to identify patients who could benefit from ICB therapy is particularly important for precision cancer treatment. However, due to the lack of a user-friendly platform, the construction of such gene signatures is a great challenge for clinical investigators who have limited programming skills. In light of this challenge, we developed a web server called Tumor Immunotherapy Response Signature Finder(TIRSF) for the construction of gene signatures to predict ICB therapy response in cancer patients. TIRSF consists of three functional modules. The first module is the Signature Discovery module which provides signature construction and performance evaluation functionalities. The second is a module for response prediction based on the TIRSF signatures, which enables response prediction and prognostic analysis of immunotherapy samples. The last is a module for response prediction based on existing signatures. This module currently integrates 24 published signatures for ICB therapy response prediction. Together, all of above features can be freely accessed at http:\/\/tirsf.renlab.org\/.<\/jats:p>","DOI":"10.1093\/nar\/gkac374","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T11:22:50Z","timestamp":1651231370000},"page":"W761-W767","source":"Crossref","is-referenced-by-count":5,"title":["TIRSF: a web server for screening gene signatures to predict Tumor immunotherapy response"],"prefix":"10.1093","volume":"50","author":[{"given":"Li","family":"Chen","sequence":"first","affiliation":[{"name":"School of Life Sciences, Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University , Guangzhou \u00a0510060,\u00a0 China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianjian","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University , Guangzhou \u00a0510060,\u00a0 China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University , Guangzhou \u00a0510060,\u00a0 China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haichen","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University , Guangzhou \u00a0510060,\u00a0 China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruihan","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University , Guangzhou \u00a0510060,\u00a0 China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihang","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University , Guangzhou \u00a0510060,\u00a0 China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Li","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University , Guangzhou \u00a0510060,\u00a0 China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2492-2689","authenticated-orcid":false,"given":"Zhixiang","family":"Zuo","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University , Guangzhou \u00a0510060,\u00a0 China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Ren","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University , Guangzhou \u00a0510060,\u00a0 China"},{"name":"State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University , Guangzhou \u00a0510060,\u00a0 China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3566-4849","authenticated-orcid":false,"given":"Yubin","family":"Xie","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University , Guangzhou \u00a0510060,\u00a0 China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"2022070423591863000_B1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.12788\/j.sder.2018.028","article-title":"Immunotherapy for melanoma","volume":"37","author":"Cuevas","year":"2018","journal-title":"Semin. Cutan. Med. Surg."},{"key":"2022070423591863000_B2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.semcancer.2017.11.019","article-title":"Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy","volume":"52","author":"Osmani","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"2022070423591863000_B3","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.3390\/ijms21072532","article-title":"Immunotherapy in renal cell carcinoma: the future is now","volume":"21","author":"Deleuze","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"2022070423591863000_B4","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.3390\/cancers13102414","article-title":"Cytotoxic T-Lymphocyte antigen-4 in colorectal cancer: another therapeutic side of capecitabine","volume":"13","author":"Derakhshani","year":"2021","journal-title":"Cancers"},{"key":"2022070423591863000_B5","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/intimm\/dxp072","article-title":"PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory t cells","volume":"21","author":"Wang","year":"2009","journal-title":"Int. Immunol."},{"key":"2022070423591863000_B6","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J. Clin. Invest."},{"key":"2022070423591863000_B7","doi-asserted-by":"crossref","first-page":"e23849","DOI":"10.4161\/onci.23849","article-title":"TIM3(+)FOXP3(+) regulatory t cells are tissue-specific promoters of T-cell dysfunction in cancer","volume":"2","author":"Sakuishi","year":"2013","journal-title":"Oncoimmunology"},{"key":"2022070423591863000_B8","first-page":"2190","article-title":"Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory t cells in non-small-cell lung cancer patients","volume":"5","author":"Wei","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"2022070423591863000_B9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/13543784.2020.1826436","article-title":"Ipilimumab: an investigational immunotherapy for glioblastoma","volume":"29","author":"Youssef","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2022070423591863000_B10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1078-0432.CCR-16-3001","article-title":"Breast cancer immunotherapy: facts and hopes","volume":"24","author":"Emens","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"2022070423591863000_B11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/14737140.2020.1732211","article-title":"Atezolizumab for the treatment of breast cancer","volume":"20","author":"Reddy","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"key":"2022070423591863000_B12","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1038\/s41467-021-22619-w","article-title":"Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"2022070423591863000_B13","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1038\/s41467-021-23244-3","article-title":"PLGA-particle vaccine carrying TLR3\/RIG-I ligand riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy","volume":"12","author":"Koerner","year":"2021","journal-title":"Nat. Commun."},{"key":"2022070423591863000_B14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2022070423591863000_B15","first-page":"839","article-title":"Epizootic of trichophyton mentagrophytes (interdigitale) in white mice","volume":"28","author":"Cetin","year":"1965","journal-title":"Pathol. Microbiol. (Basel)"},{"key":"2022070423591863000_B16","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of t cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"2022070423591863000_B17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41574-018-0089-y","article-title":"Muscle circadian clock regulates lipid storage","volume":"14","author":"Leong","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"2022070423591863000_B18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"2022070423591863000_B19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"2022070423591863000_B20","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"key":"2022070423591863000_B21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"2022070423591863000_B22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science (New York, N.Y.)"},{"key":"2022070423591863000_B23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep."},{"key":"2022070423591863000_B24","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of t cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"2022070423591863000_B25","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat. Med."},{"key":"2022070423591863000_B26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-pd-1 monotherapy and anti-pd-1\/anti-ctla-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"2022070423591863000_B27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"2022070423591863000_B28","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1002\/sim.5958","article-title":"Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks","volume":"32","author":"Blanche","year":"2013","journal-title":"Stat. Med."},{"key":"2022070423591863000_B29","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1038\/s41467-019-12160-2","article-title":"B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma","volume":"10","author":"Griss","year":"2019","journal-title":"Nat. Commun."},{"key":"2022070423591863000_B30","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"2022070423591863000_B31","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.3389\/fimmu.2020.02105","article-title":"Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma","volume":"11","author":"Maibach","year":"2020","journal-title":"Front. Immunol."},{"key":"2022070423591863000_B32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","article-title":"Clinical significance of tumor-infiltrating lymphocytes in breast cancer","volume":"4","author":"Stanton","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"2022070423591863000_B33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"2022070423591863000_B34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol."},{"key":"2022070423591863000_B35","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol."}],"container-title":["Nucleic Acids Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nar\/article-pdf\/50\/W1\/W761\/44378783\/gkac374.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nar\/article-pdf\/50\/W1\/W761\/44378783\/gkac374.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:03:04Z","timestamp":1656979384000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nar\/article\/50\/W1\/W761\/6584779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":35,"journal-issue":{"issue":"W1","published-online":{"date-parts":[[2022,5,12]]},"published-print":{"date-parts":[[2022,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/nar\/gkac374","relation":{},"ISSN":["0305-1048","1362-4962"],"issn-type":[{"type":"print","value":"0305-1048"},{"type":"electronic","value":"1362-4962"}],"subject":[],"published-other":{"date-parts":[[2022,7,5]]},"published":{"date-parts":[[2022,5,12]]}}}